<DOC>
	<DOCNO>NCT00626522</DOCNO>
	<brief_summary>The study seek determine optimal dose Aclidinium/Formoterol combination investigation Phase III clinical trial</brief_summary>
	<brief_title>Aclidinium/Formoterol Fixed Combination Dose Finding Study</brief_title>
	<detailed_description>Dose-finding clinical trial , assess efficacy , safety pharmacokinetics three different dos formoterol combine inhaled anticholinergic aclidinium bromide , aclidinium bromide monotherapy formoterol monotherapy</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<criteria>1 . Adult male nonpregnant , nonlactating female age 40 80 year old , inclusive . Women childbearing potential allow enter trial use two medically approve contraceptive measure ( ie , mechanical pharmacological ) . ( A female consider childbearing potential unless hysterectomy , least one year postmenopause undergone tubal ligation . All woman childbearing potential negative serum pregnancy test Screening Visit ) . 2 . Patients clinical diagnosis stable moderate severe COPD ( stage II III ) accord GOLD 2006 classification ( http : //www.goldcopd.com ) . 3 . Current excigarette smoker smoke history least 10 packyears . Packyears calculate divide number cigarette smoke per day 20 ( number cigarettes pack ) multiply figure number year person smoke . For example , person smoke 40 cigarette day smoke 10 year would 20 packyear smoke history ( 40 cigarette per day ÷ 20 cigarette per pack = 2 ; 2 x 10 year smoke = 20 packyear history ) . Patients smoke tobacco type allow , unless meet cigarette criterion well . 4 . Patients whose Forced Expiratory Volume 1 second ( FEV1 ) Screening Visit measure 3045 minute post inhalation 400 μg salbutamol 30 % ≤FEV1 &lt; 80 % predict normal value ( ie , 100 x Postsalbutamol FEV1/Predicted FEV1 &lt; 80 % ≥30 % ) . ( Predicted normal value use calculation purpose base European Community Steel Coal predict value ) 5 . Patients whose FEV1/Forced Vital Capacity ( FVC ) Screening Visit measure 30 45 minute post inhalation 400 μg salbutamol &lt; 70 % ( ie , 100 x Postsalbutamol FEV1/FVC &lt; 70 % ) . 6 . Patients whose COPD symptoms FEV1 value time randomisation stable compare Screening Visit , accord Investigator 's medical judgment . 7 . Patients eligible able participate trial consent write purpose nature investigation explain . 1 . History current diagnosis asthma , allergic rhinitis atopy , exerciseinduced bronchospasm . 2 . Eosinophil count ≥600 cells/mm3 . 3 . Clinically significant respiratory condition time Screening Visit define : Use longterm oxygen therapy &gt; 5 h/day , Known active tuberculosis , History interstitial lung pulmonary thromboembolic disease , Pulmonary resection past 12 month , History lifethreatening COPD , History bronchiectasis secondary respiratory diseases others COPD ( eg , cystic fibrosis , Kartagener 's syndrome , etc ) , Patients Investigator 's opinion may need stop start pulmonary rehabilitation undergo thoracotomy trial , 4 . Hospitalisation due COPD exacerbation , 3 month prior Screening Visit . 5 . Signs COPD exacerbation respiratory infection ( include upper respiratory tract ) , 6 week prior Screening Visit . 6 . Clinically significant cardiovascular condition time Screening Visit define : Myocardial infarction within previous 6 month , Unstable arrhythmia require change pharmacological therapy intervention within previous 12 month , newly diagnose arrhythmia within previous 3 month . Hospitalisation within previous 12 month heart failure functional class III ( marked limitation activity comfortable rest ) IV ( need complete rest , confinement bed chair , discomfort physical activity presence symptom rest ) per New York Heart Association classification ( www.americanheart.org ) Thoracic surgery within previous 24 month 7 . Presence symptomatic prostatic hypertrophy and/or bladder neck obstruction . ( However , patient diagnosis condition without symptom due stable concomitant medication treatment allow enter trial ) . 8 . Presence narrowangle glaucoma . 9 . History untoward reaction know hypersensitivity inhale anticholinergic ( include aclidinium bromide ) , β2 adrenergic agonist inhale medication component thereof ( include report paradoxical bronchospasm ) . 10 . Life expectancy less 1 year . 11 . Prolonged QT interval correct use Bazett 's formula ( QTcB ) interval ( &gt; 470 msec ) ECGs perform randomisation , and/or use drug may induce prolongation . 12 . Clinically relevant abnormality laboratory result , ECG parameter ( QTcB ) , physical examination abnormality define disease state list exclusion criterion , except related COPD . 13 . Clinically significant disease COPD , , opinion Investigator , may put patient risk participation trial ; disease may influence result study patient 's ability take part . 14 . Patients maintain regular day/night , waking/sleeping cycle ( eg , night shift worker exclude ) . 15 . Patients intend use concomitant medication permit protocol undergone require washout period particular prohibit medication . 16 . Patients unable unlikely cooperative study requirement take medication , completion Patient Diary attend clinic study visit . 17 . Patients unable properly use dry powder pressurise metereddose inhaler ( pMDI ) inhaler device and/or perform acceptable reproducible spirometry measurement per ATS/ERS standard ( Standardisation lung function test , 2005 20 ) . 18 . History drug and/or alcohol abuse addiction previous 2 year . 19 . Previous participation another clinical trial investigational medicinal product 6 week prior Screening Visit . ( Patients participate previous clinical trial aclidinium bromide ( Almirall product code LAS34273 ) allow participate study provide criterion fulfil . This circumstance specifically record eCRF ) .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Bronchitis</keyword>
	<keyword>Chronic</keyword>
	<keyword>Emphysema</keyword>
	<keyword>Smokers ex-Smokers</keyword>
</DOC>